Amgen (AMGN)
$310.73
0.15 (0.05%)
AMGN Stock Quote Delayed 30 Minutes
AMGN Looks Compelling After Earnings, Despite Brewing Headwinds
The Amgen earnings report for Q3 reinvigorated AMGN shares, for all the right reasons.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
355,882
Day's Range
$310.61 - $315.48
52-Week Range
$218.61 - $329.72
Dividend & Yield
$8.52 (2.74%)
AMGN Stock Predictions, Articles, and Amgen News
Biggest Movers in Healthcare Stocks Now – CNMD MDCO CBM REGN
Healthcare stocks remained flat on Monday morning on Wall Street.
Biggest Movers in Healthcare Stocks Now – EXAS REGN AMGN CELG
Healthcare stocks rose broadly on Wall Street on Wednesday morning, with the sector seeing an overall increase of 0.7%.
Be Careful Before Loving Leveraged Biotech ETFs
The new crop of triple-leveraged biotech ETFs have had staggering returns (and losses), serving as a reminder that not all investors should be involved with leveraged ETFs.
Wall Street Hit as the Dow Jones Tests 16,000
Stocks are still in the midst of their "hike or no hike" anxiety attack, while the weakness is backed up by government action against Big Pharma and disappointing economic data from China, sending the Dow Jones lower.
Stocks Move Lower on Continued Weakness in Biotech
Financials were the winners of the day, while the selloff in biotech pressured all indices but the Dow Jones, which Nike (NKE) propped up on strong earnings.
Biotech Stocks: Is It Safe to Come out Now? (IBB, XBI)
Biotech stocks are getting smashed this week, but betting against the sector remains a bad idea. The only trick is getting the timing right.
Fill a Prescription for a Bear Put Spread in Amgen Stock (AMGN)
Bearish technicals, expensive option premiums and limited risk are the right formula for an Amgen stock bear vertical put spread.
U.S. Debut of Biosimilar Drugs Threatens Major Biotechs
The introduction of biosimilar drugs will change the biotech landscape ... especially for these three names.
Should You Buy Amgen Stock? 3 Pros, 3 Cons (AMGN)
If Amgen stock is going to move higher or lower in the foreseeable future, it could hinge on new AMGN drugs in the pipeline -- or the looming competition of biosimilars.
Why Twitter Inc (TWTR), J C Penney Company Inc (JCP) and The Medicines Company (MDCO) Are 3 of Today’s Best Stocks
Concerns over China and the Fed sent Wall Street lower on Monday, but Twitter, JCPenney and The Medicines Company bucked the trend.
Biggest Movers in Healthcare Stocks Now – MDCO THRX ALNY FOLD
Healthcare stocks remained flat on Monday morning on Wall Street.
7 Best American Funds for the Long-Term Investor
The best American Funds have a solid history of benchmark-beating, long-term performance.
Biggest Movers in Healthcare Stocks Now – SRPT EBS EXAM MSA
Healthcare stocks rose broadly on Wall Street on Monday, with the sector seeing an overall increase of 0.8%.
Hottest Healthcare Stocks Now – ENDP NLNK IDXX IPXL
Healthcare stocks finished down broadly on Wall Street today, with the sector seeing an overall decline of 0.2%.
Trade of the Day: AMGN Stock Could Jump 20%-Plus in 3 Months
A post-earnings breakout in Amgen, Inc. was assisted by very high buy-side volume.
AMGN Stock: The Dark Underbelly of Amgen Earnings
Amagen reported a stellar-looking earnings report, but a lot of its revenue increases were due to price hikes and not higher adoption.
